Minocycline's higher lipophilicity than other tetracyclines drives deeper CNS and tissue penetration, and the more pronounced vestibular, autoimmune and pigmentation monitoring that comes with it, across the tablet, capsule and injection lines M Care exports.
Minocycline is markedly more lipophilic than doxycycline and other tetracyclines, giving it deeper penetration into the central nervous system, skin and other soft tissue, which is why it remains a distinct choice among tetracycline-class antibacterials for systemic therapy. That same property drives a monitoring profile procurement teams should not overlook: vestibular symptoms, drug-induced lupus-like syndrome and autoimmune hepatitis with long-term therapy, and skin or mucosal pigmentation. M Care exports minocycline tablets, capsules and injection, sourced from WHO-GMP certified Indian manufacturers, to regulated and semi-regulated markets.
Minocycline exporter and bulk supplier from India.
Minocycline tablets, capsules and injection are shipped against a standard pre-shipment export documentation set: certificate of analysis per batch, certificate of pharmaceutical product or free sale certificate, packing list, commercial invoice, and CDSCO-endorsed export documentation. As a tetracycline-class molecule, minocycline stock is packed to limit moisture and light exposure, in blister strips or amber containers with appropriate desiccant, which matters for consignments moving into humid Gulf, West African and Southeast Asian climates. Injection vials are packed and labelled for transit per the product's approved storage conditions, verified against the manufacturer's stability data before dispatch. Buyers should confirm their own import permit and destination marketing authorization before order confirmation, since M Care exports on Indian manufacturing and export documentation, not a destination-market registration it holds itself.
Source
WHO-GMP-certified Indian manufacturing line, named on every quote.
Minimum order
No blanket MOQ. Set by the source manufacturer's minimum batch-release quantity for the strength and pack ordered.
Pricing
On request. Indicative FOB or CIF quote, formal proforma on confirmation.
Incoterms
EXW, FOB, CIF, CIP or DAP.
Payment
Letter of credit (sight or usance) and telegraphic transfer.
Documentation
WHO-GMP certificate of the source line, product-specific CoPP, batch CoA, method of analysis, Free Sale Certificate, Certificate of Origin, CTD or eCTD dossier. On request.
Shelf-life
Minimum remaining shelf-life agreed per order and confirmed on the proforma.
Response
Availability and CoPP status within two working days; pre-alert documents before dispatch.
Tetracycline-class antibacterial (second-generation semisynthetic tetracycline), sourced and documented for export.
Minocycline's higher lipophilicity than other tetracyclines gives it deeper penetration into the central nervous system, skin and connective tissue, a pharmacokinetic distinction that shapes both its clinical use and its safety monitoring. It is a second-generation semisynthetic tetracycline-class antibacterial active against a broad range of Gram-positive and Gram-negative organisms, atypical pathogens, and some anaerobes, and its tissue penetration makes it a recurring choice where a tetracycline is indicated for infections outside straightforward skin or respiratory sites. The same lipophilicity that carries it into tissue also carries a more pronounced vestibular, autoimmune and pigmentation signal than other tetracyclines show, so regulatory and clinical teams evaluating a minocycline line are usually comparing it against doxycycline on exactly this trade-off, not on spectrum alone. M Care supplies immediate-release tablets, capsules including modified-release formats, and injection, all single-agent, none combination products.
Active ingredient
Minocycline hydrochloride. Tetracycline-class antibacterial (second-generation semisynthetic tetracycline).
Forms and strengths
45 mg; 50 mg; 65 mg; 100 mg.
Indications
Minocycline is a broad-spectrum, second-generation semisynthetic tetracycline antibacterial distinguished by higher lipophilicity than other tetracyclines, giving it greater penetration into the central nervous system and soft tissue. M Care supplies it as oral tablets, capsules (including modified-release formats) and injection, all single-agent lines sourced from WHO-GMP certified Indian manufacturers for export.
Administration
Oral, Intravenous. Tablet, capsule (including modified-release) and injection for intravenous infusion.
Documentation
Batch-specific CoA, CoPP, manufacturing-site WHO-GMP certificate and stability data compiled per consignment, in the format the destination regulator expects.
Hospital pharmacies, licensed importers and tender desks across our export markets.
India is our origin. We do not sell into the Indian market.
Demand for minocycline comes from hospital procurement and tender desks handling systemic infections where tissue or CNS penetration matters, dermatology-linked prescribing programmes managing long-term acne therapy under specialist supervision, and licensed importers building tetracycline-class formulary depth alongside doxycycline. Regulatory affairs teams evaluating a new supplier for dossier submission are a recurring buyer type, given the molecule's distinct adverse-effect labelling requirements. M Care's export activity in minocycline concentrates on the UK and EU, Gulf and GCC procurement channels, African importers and government tenders, Latin American distributors, Southeast Asian wholesalers and CIS markets. India is the country of manufacture only and is not a served market for any M Care export line.
GCC registration routes
Supply against MoH registration held by your local licensed importer, or via the GCC central registration pathway.
UK unlicensed routes
Where no UK licence exists, the MHRA Specials and named-patient import routes cover clinically justified demand.
Tender desks
Bid-pack documentation assembled to the tender's specification, from CoPP to batch records.
Dossier support
CTD documentation from the sourcing manufacturer, compiled for your regulator's format.
What the dispensing pharmacist checks on minocycline.
A reviewing pharmacist checks baseline and periodic liver function tests and, where autoimmune symptoms such as arthralgia, fever or malaise appear, ANA and CBC, since minocycline's long-term use is associated with drug-induced lupus-like syndrome, autoimmune hepatitis and vasculitis more often than shorter-acting tetracyclines, per the approved label. Vestibular effects (dizziness, vertigo, tinnitus) occur in a meaningful minority of patients and are counselled distinctly from other tetracycline-class agents because of minocycline's greater CNS penetration; this is relevant to occupational counselling in hospital-supplied stock. Skin, oral mucosa and dental pigmentation is documented with prolonged administration and, unusually, has been reported independent of cumulative dose in some cases, so it is flagged separately from the dose-dependent pigmentation seen with older tetracyclines. Cross-sensitivity within the tetracycline class applies. Use in children under eight years and in pregnancy is not indicated because of permanent tooth discoloration and inhibition of bone growth, a class-wide constraint the pharmacist confirms is reflected in the batch labelling and package insert supplied with the consignment.
The documentation pack a regulator actually asks for.
Every minocycline consignment ships with a certificate of analysis matched to the batch, a certificate of pharmaceutical product or free sale certificate, and CDSCO export documentation confirming the line is cleared for export from India. M Care's own credentials are ISO 9001:2015 for its quality management system and a CDSCO export licence; M Care is a merchant-exporter and does not hold, and does not claim, WHO-GMP or WHO-PQ certification, since those apply to the manufacturing site, not to a trading entity. Source manufacturers are WHO-GMP certified and documentation packages are matched to buyer requirements, including stability data addressing the molecule's sensitivity to light and moisture. Because minocycline carries tetracycline-class labelling obligations, regulatory dossiers should confirm the batch insert reflects current pediatric, pregnancy and autoimmune-risk warnings rather than an outdated label version. In India, minocycline is a Schedule H prescription drug, not a narcotic or psychotropic-scheduled substance, and every line M Care lists is a single-agent formulation with no fixed-dose combination in the current 26-line catalogue.
CoA and MoA, per batch
Batch-specific certificate and method of analysis from the sourcing manufacturer's QC release.
CoPP, WHO-GMP, MFG licence
Certificate of pharmaceutical product and site GMP certification issued via CDSCO channels, naming the actual manufacturing site.
CTD Module 3
Chemistry, manufacturing and controls documentation available from the sourcing manufacturer for registration filings.
Pack insert, labels, artwork
Destination-language patient information and labelling to the local regulator's standard, locked before shipment.
Pharmacovigilance
A named PV contact arranged in the destination market where the registration requires one.
What a buyer should know before this line enters a formulary.
We publish the awkward facts alongside the useful ones. A supplier who omits them is not saving you work, only deferring it.
Prescription-only (Schedule H in India); not a narcotic or psychotropic-scheduled substance
Not indicated for children under eight years or in pregnancy: risk of permanent tooth discoloration and inhibition of bone growth (class-wide tetracycline warning)
Long-term use associated with drug-induced lupus-like syndrome, autoimmune hepatitis and vasculitis; liver function tests, ANA and CBC monitoring recommended if symptomatic
Vestibular adverse effects (dizziness, vertigo, tinnitus) reported more frequently than with other tetracyclines due to higher CNS penetration
Skin, oral mucosa and dental pigmentation reported with prolonged use, in some cases independent of cumulative dose
Cross-sensitivity applies across the tetracycline class; photosensitivity reactions are possible
Adjacent lines procurement desks order alongside minocycline.
Molecule · strength · volume · destination. One working day to a quote.
- Send us the specifics. Form and strength, pack preference, destination market and indicative volume for minocycline.
- We route to the right line. The enquiry goes to the WHO-GMP certified manufacturing partner whose certificates fit your regulator.
- Commercial and regulatory offer. FOB or CIF price with the documentation list, named manufacturing site and current certificate validity.
- Order, produce, release, ship. QC release on the Indian side, batch documents compiled, despatch on the agreed incoterm.
- After delivery. Batch records and certificates archived and retrievable for the life of the product on your shelf.
Minocycline supply, the specific questions.
Does M Care hold WHO-GMP or WHO-PQ certification directly?
No. M Care is a merchant-exporter, not a manufacturer, so it does not hold WHO-GMP or WHO-PQ certification itself; those apply to a manufacturing site. M Care's own credentials are ISO 9001:2015 and a CDSCO export licence, and its minocycline lines are sourced from WHO-GMP certified Indian manufacturers.
How does minocycline differ from doxycycline for a tender or formulary decision?
Minocycline is markedly more lipophilic, giving it deeper CNS and tissue penetration, but this same property is associated with a more pronounced vestibular, autoimmune-hepatitis/lupus-like and pigmentation signal on long-term therapy than doxycycline typically shows. A formulary decision between the two should weigh that trade-off against the clinical indication, not spectrum alone.
What is minocycline's main long-term safety concern that a regulatory dossier should reflect?
Long-term minocycline use is associated with drug-induced lupus-like syndrome, autoimmune hepatitis, vasculitis, and skin, mucosal or dental pigmentation, alongside vestibular symptoms such as dizziness and vertigo. Buyers should confirm their batch package insert reflects current labelling on these risks before distribution.
Which dosage forms does M Care actually stock for minocycline?
M Care's 26 minocycline lines cover immediate-release oral tablets, capsules including modified-release (once-daily) formats, and injection for intravenous use. M Care does not stock minocycline oral suspension, topical, ophthalmic, inhaled or sachet presentations.
Is minocycline suitable for pediatric or pregnant patient populations?
No. Like other tetracycline-class drugs, minocycline is not indicated for children under eight years or during pregnancy, because of the risk of permanent tooth discoloration and inhibition of bone growth. This is a class-wide constraint reflected in the approved product labelling.
What documentation accompanies a minocycline export consignment?
Each consignment ships with a batch-matched certificate of analysis, a certificate of pharmaceutical product or free sale certificate, a packing list, commercial invoice and CDSCO export documentation. Buyers requiring additional stability or regulatory data for their own dossier should raise this before order confirmation.
Is minocycline a controlled or scheduled substance in India?
No. Minocycline is a prescription-only (Schedule H) drug in India, not a narcotic or psychotropic-scheduled substance. Export documentation and packing reflect standard prescription-only handling, not controlled-substance requirements.
Who stands behind this page, and where its statements come from.
Reviewed by Dr. Rajat Bhatt, PharmD, Managing Director, M Care Exports. Last reviewed 2026-08-22.
This page is sourcing information for licensed importers, hospital procurement and tender desks. It is not medical, pharmaceutical or prescribing advice, and it is not a substitute for the approved product information of the line on your order. See our full disclaimer.
Send the specifics. You'll have a price inside one working day.
Form and strength, destination market and indicative volume. The Mumbai desk replies within one working day, including when the honest answer is that the route is not viable yet.